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pisk of Noncardiac Surgery in
he Months Following Placement
f a Drug-Eluting Coronary Stent
e read with great interest the retrospective study by Wilson et al.
1) in a recent issue of the Journal. The study provides data
uggesting that, whenever possible, noncardiac surgery should be
elayed six weeks after placement of a coronary stent. By that time
course of antiplatelet therapy to prevent stent thrombosis has
sually been completed, and bare metal stents are generally
ndothelialized.
Today, drug-eluting stents are increasingly utilized to reduce
he risk of restenosis. Elution of antiproliferative agents delays
ndothelialization (2,3), which, consequently, may increase the risk
f subacute and late stent thrombosis. Therefore, a prolonged
ourse of antiplatelet therapy has been recommended with the use
f drug-eluting stents (4). Thus, the conclusion drawn from the
tudy by Wilson et al. (1) is strictly confined to bare metal stents
nd is not applicable for drug-eluting stents.
We recently observed a patient who simultaneously received a
are metal stent (3.5  13 mm at right coronary artery [RCA])
nd two paclitaxel-eluting stents (both 2.5  16 mm at the left
ircumflex coronary artery [LCX]) for stable angina and double-
essel coronary artery disease. A six-month course of combined
ntiplatelet therapy (clopidogrel 75 mg daily and aspirin 100 mg
aily) to prevent stent thrombosis was prescribed. At 12 weeks
ollowing stent placement, surgery for meniscopathy at the left
nee was performed after cessation of both antiplatelet agents.
wo hours following surgery, the patient developed chest pain.
ubsequently, myocardial infarction (MI) was confirmed by elec-
rocardiography and by biochemical markers. The patient was
ransferred to our institution one day after surgery for cardiac
atheterization. Coronary angiography revealed total occlusion of
oth paclitaxel-eluting stents at the LCX. The bare stent at the
CA was unremarkable. Recanalization of the occluded stents was
erformed successfully.
Stent thrombosis is a highly morbid complication of coronary
tenting (5,6). With the use of combined antiplatelet therapy, the
requency of stent thrombosis has been reduced dramatically (7).
owever, noncardiac surgery soon after coronary stenting is
ssociated with a high rate of MI and death (8). The present data
1) nicely demonstrate that delaying noncardiac surgery for up to
ix weeks after stent placement and completing a course of
ntiplatelet therapy with a thienopyridine is associated with a low
requency of stent thrombosis and other adverse events. However,
his recommendation has to be strictly confined to bare metal
tents. Following drug-eluting stent placement, elective noncardiac
urgery should be delayed for several months, by which time those
tents are generally endothelialized, and a course of prolonged
ombined antiplatelet therapy to prevent stent thrombosis has been
ompleted.
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ercutaneous Coronary
ntervention Before Noncardiac
urgery: More Threat Than Benefit?
e read with great interest the report by Wilson et al. (1) entitled
Clinical Outcome of Patients Undergoing Non-Cardiac Surgery
n the Two Months Following Coronary Stenting.” This very
nteresting study supports previous evidence that both percutane-
us transluminal coronary angioplasty (PTCA) and coronary
tenting increase adverse perioperative cardiac events (2–4).
In their study, the investigators reported that 8 (4%) of 207
atients undergoing noncardiac surgery (NCS) in the two months
ollowing successful coronary stenting had major adverse cardiac
vents. All 8 patients were among the 168 patients who underwent
urgery within six weeks after coronary stent placement. No major
vents were observed in the remaining 39 patients undergoing
urgery 6 weeks after stent placement. These data indicate that
he risk of stent thrombosis is increased when surgery is carried out
n the six weeks following the coronary intervention. In contrast to
rior reports (3,4), Wilson et al. (1) did not identify an increased
ncidence of major hemorrhagic complications in the study popu-
ation. As the researchers wisely stated in their study, the inability
o determine a relationship among antiplatelet therapy, time to
urgery, and bleeding should be interpreted with great caution.
arge prospective studies will be necessary to clarify the results
rovided by the available small retrospective studies.
We recently performed a systematic review of the available
iterature in this regard (C. E. Mendoza et al., unpublished data,
